Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 3M Company (MMM) vs Sana Biotechnology Inc (SANA) Price & Performance

3M CompanyTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

3M Company vs Sana Biotechnology Inc — how do they compare? 3M Company trades at $183.32 (market cap $94.44B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: 3M Company is far larger — about 83.6× Sana Biotechnology Inc's market cap, and 3M Company pays a 1.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

MMMSANA
Market Cap
$94.44B$1.13B
Sector
IndustrialsHealth
52-Week High
$183.13$5.92
52-Week Low
$141.10$2.68
Enterprise Value
$103.67B$1.05B
Dividend Yield
1.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

3M Company

3M (MMM) trades at $184.15, up 1.16% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates and raising full-year guidance, driven by growth in Safety & Industrial and Transport & Electronics segments. Financial health is solid with a net income margin of 11.9% and robust cash flow, though valuation ratios like P/E of 32.53 appear elevated. Recent news highlights innovation in high-growth verticals and a partnership with Microsoft on EBO technology.

The outlook for MMM is positive due to operational improvements and raised guidance, but risks include high valuation, ongoing litigation, and macroeconomic pressures. Analyst sentiment is mixed with a consensus price target of $173.00 below the current price, suggesting cautious optimism. Investors should weigh strong fundamentals against potential headwinds for balanced decision-making.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

Read more on MMM

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA